Kura Oncology, Inc. (KURA) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$9.17

From 52W high−31.13%

Volume2.15M

Market cap$832.67M

P/E (TTM)—

P/S (TTM)10.8x

Div yield—

Key dataOct 19, 2026

Open

$9.17

From 52W high

−31.13%

Volume

2.15M

Market cap

$832.67M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.1x

P/E (TTM)

—

RSI (14)

28.4

MomentumView details →

1D Return

+3.08%

YTD Return

−11.07%

SummaryUpdated Jun 1, 2026

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. The company went public in September 2015 and focuses on developing precision medicines for cancer treatment. Kura has built a pipeline of small molecule drug candidates designed to target specific genetic mutations and pathways involved in various cancers, with its lead programs showing particular promise in blood cancers like acute myeloid leukemia (AML) and solid tumors including gastrointestinal stromal tumors (GIST).

Ask drillr about Kura Oncology, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.1x

EV/Sales

4.4x

P/S (TTM)

10.8x

P/B (TTM)

17.2x

ProfitabilityView details →

Gross Margin

94.73%

Net Margin

−384.30%

EBITDA Margin

−381.19%

ROE (TTM)

−612.78%

ROA (TTM)

−50.49%

Asset Turnover

0.12x

GrowthView details →

Revenue YoY

−7.27%

EPS YoY

−49.12%

FCF YoY

—

Revenue CAGR 3Y

+25.24%

EPS CAGR 3Y

−57.43%

EBITDA YoY

−52.35%

MomentumView details →

1D Return

+3.08%

YTD Return

−11.07%

1Y Return

−7.51%

RSI (14)

28.4

vs 50D SMA

−18.32%

vs 200D SMA

−5.56%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

4.73x

Quick Ratio

4.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.77

EPS Surprise

12.23%

Beats (12Q)

8/12

Next Q EPS Est

−$0.82

Avg Surprise (4Q)

−156.52%

Rev Surprise

3.53%

Financials snapshotView financials →

Revenue (TTM)

77.22M

Net Income (TTM)

−296.77M

Op. CF (TTM)

−111.76M

Next earningsNov 3, 2026 →

Latest newsMore news →

Caspian Therapeutics and Kura Oncology, Inc. announced that they will host an investor webcast on October 13, 2026, at 4:30 p.m. ET to discuss Caspian's launch and preclinical data for KO-7246 in diabetes.13d ago

Similar companies

MoonLake ImmunotherapeuticsMLTX Arbutus Biopharma CorporationABUS Aktis Oncology, Inc.AKTS SpyGlass Pharma, Inc. Common StockSGP Alumis Inc. Common StockALMS Corvus Pharmaceuticals, Inc.CRVS Find similar companies →

Latest newsMore news →

Caspian Therapeutics and Kura Oncology, Inc. announced that IND-enabling development of KO-7246 is underway to support a planned Phase 1 proof-of-concept study assessing safety and endogenous insulin production.7d ago Caspian Therapeutics and Kura Oncology, Inc. announced that they will host an investor webcast on October 13, 2026, at 4:30 p.m. ET to discuss Caspian's launch and preclinical data for KO-7246 in diabetes.13d ago Kura Oncology launched Caspian Therapeutics, a separately financed company to advance menin inhibitors for diabetes, with $50 million financing led by BVF Partners.41d ago